Get the Stockscreener App
77.44
6.02%
4.40
After Hours:
77.50
0.06
+0.08%
Monopar Therapeutics Inc stock is traded at $77.44, with a volume of 66,908.
It is up +6.02% in the last 24 hours and up +154.57% over the past month.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.
See More
Previous Close:
$73.04
Open:
$74.88
24h Volume:
66,908
Relative Volume:
1.33
Market Cap:
$477.80M
Revenue:
-
Net Income/Loss:
$-7.12M
P/E Ratio:
-33.67
EPS:
-2.3
Net Cash Flow:
$-6.82M
1W Performance:
+16.89%
1M Performance:
+154.57%
6M Performance:
+106.07%
1Y Performance:
+1,398%
1-Day Range:
$68.16
$79.80
1-Week Range:
$60.43
$79.80
52-Week Range:
$4.50
$79.80
Monopar Therapeutics Inc Stock (MNPR) Company Profile
Name
Monopar Therapeutics Inc
Sector
Industry
Phone
(847) 388-0349
Address
1000 SKOKIE BLVD SUITE 350, WILMETTE
Compare MNPR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MNPR
Monopar Therapeutics Inc
|
77.44 | 450.65M | 0 | -7.12M | -6.82M | -2.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
381.87 | 96.56B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
449.58 | 60.08B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
555.51 | 61.15B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
711.09 | 44.66B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
328.71 | 36.23B | 3.81B | -644.79M | -669.77M | -6.24 |
Monopar Therapeutics Inc Stock (MNPR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-09-25 | Initiated | BTIG Research | Buy |
| Sep-03-25 | Initiated | Oppenheimer | Outperform |
| Sep-03-25 | Initiated | Raymond James | Strong Buy |
| Aug-26-25 | Resumed | H.C. Wainwright | Buy |
| Jul-07-25 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-23-25 | Initiated | Chardan Capital Markets | Buy |
| Mar-19-25 | Resumed | Piper Sandler | Overweight |
| Jan-10-25 | Initiated | Piper Sandler | Overweight |
| Oct-11-24 | Initiated | Rodman & Renshaw | Buy |
| Jan-28-21 | Initiated | ROTH Capital | Buy |
View All
Monopar Therapeutics Inc Stock (MNPR) Latest News
Monopar Therapeutics stock price target raised to $95 by Piper Sandler - Investing.com India
Monopar Therapeutics Announces Underwriting Agreement for Stock Sale - MSN
Piper Sandler Raises Monopar Therapeutics (MNPR) Price Target to - GuruFocus
MNPR: BTIG Raises Price Target on Monopar Therapeutics to $104 | - GuruFocus
Monopar Therapeutics (MNPR): Chardan Capital Raises Price Target - GuruFocus
Chardan Raises Price Target on Monopar Therapeutics to $85 From $60, Keeps Buy Rating - MarketScreener
Goldman Sachs Group Inc. Takes $673,000 Position in Monopar Therapeutics Inc. $MNPR - Defense World
Monopar Therapeutics stock price target raised to $104 by BTIG - Investing.com Canada
Positive Outlook for Monopar Therapeutics’ ALXN1840 Amid New Copper Balance Findings - TipRanks
Lake Street Maintains Monopar Therapeutics(MNPR.US) With Buy Rating, Maintains Target Price $106 - 富途牛牛
Monopar Therapeutics (MNPR) Sees Share Increase Amid Positive St - GuruFocus
Monopar jumps after doctor letter in Journal of Hepatology - TipRanks
How to integrate Monopar Therapeutics Inc. into portfolio analysis toolsEarnings Performance Report & Risk Managed Investment Entry Signals - newser.com
Monopar Therapeutics Prices $135 Million Offering of Common Stock, Pre-Funded Warrants - MarketScreener
Monopar Therapeutics (MNPR) Launches $100M Stock Offering - GuruFocus
Monopar Therapeutics prices $100 million stock offering - Investing.com
Monopar Announces Pricing Of $19.2 Mln Public Offering Of Common Stock - Nasdaq
$135 Million Raise: Biotech Monopar Therapeutics Prices Major Stock Offering with $35M Buyback Plan - Stock Titan
Monopar Therapeutics Inc. Announces Pricing of $135 Million Underwritten Offering of Common Stock and Pre-Funded Warrants - The Manila Times
Monopar Announces Journal of Hepatology Publishes Physicians’ Letter to the Editor Demonstrating ALXN1840 Rapidly Improved Copper Balance in Wilson Disease Patients - The Manila Times
Monopar Therapeutics announces pricing of $135 million underwritten offering of common stock and pre-funded warrants - MarketScreener
Breakthrough: -0.367mg Daily Copper ReductionMonopar's Drug Shows Promise for Wilson Disease Patients - Stock Titan
Monopar Therapeutics Inc. Reports Peer-Reviewed Publication Highlighting ALXN1840's Efficacy in Improving Copper Balance for Wilson Disease Patients - Quiver Quantitative
Monopar Therapeutics Inc. Announces Pricing of $135 Million Underwritten Offering of Common Stock and Pre-Funded Warrants - GlobeNewswire Inc.
Lake Street Initiates Coverage of Monopar Therapeutics (MNPR) with Buy Recommendation - Nasdaq
Lake Street Initiates Monopar Therapeutics at Buy With $106 Price Target - MarketScreener
Full technical analysis of Monopar Therapeutics Inc. stockEarnings Miss & Community Supported Trade Ideas - newser.com
Monopar Therapeutics (MNPR) Hosts Virtual Meeting with Piper San - GuruFocus
Risk adjusted return profile for Monopar Therapeutics Inc. analyzed2025 Major Catalysts & Verified High Yield Trade Plans - newser.com
Using portfolio simulators with Monopar Therapeutics Inc. includedGap Down & Stepwise Trade Signal Implementation - newser.com
Monopar Therapeutics Inc.(NasdaqCM: MNPR) added to S&P Global BMI Index - MarketScreener
Monopar Therapeutics Hits New 52-Week High of $54.54 - Markets Mojo
Monopar Therapeutics (NASDAQ:MNPR) Given "Buy" Rating at Chardan Capital - MarketBeat
Aug Fed Impact: Can DXLG keep up with sector leadersTrade Exit Summary & Real-Time Volume Triggers - khodrobank.com
Can volume confirm reversal in Monopar Therapeutics Inc.Earnings Summary Report & Detailed Earnings Play Alerts - newser.com
BTIG Research Reaffirms "Buy" Rating for Monopar Therapeutics (NASDAQ:MNPR) - MarketBeat
Analyzing Monopar Therapeutics Inc. with risk reward ratio chartsEarnings Growth Summary & Low Drawdown Investment Ideas - newser.com
Forecast Cut: How liquid is MMSI stock2025 Momentum Check & Risk Adjusted Buy/Sell Alerts - khodrobank.com
Analyzing recovery setups for Monopar Therapeutics Inc. investorsDay Trade & Community Consensus Trade Alerts - newser.com
Breakouts Watch: Does Skeena Resources Limited have declining or rising EPS2025 Volatility Report & Capital Efficiency Focused Ideas - khodrobank.com
Macro Review: Does Monopar Therapeutics Inc stock have upside surprise potentialOil Prices & Weekly Return Optimization Alerts - خودرو بانک
Can trapped investors hope for a rebound in Monopar Therapeutics Inc.July 2025 Summary & High Yield Equity Trading Tips - newser.com
What MACD and RSI say about Monopar Therapeutics Inc.Portfolio Gains Report & Accurate Buy Signal Notifications - newser.com
Monopar Therapeutics Stock Soars to New 52-Week High of $58.94 - Markets Mojo
Monopar Therapeutics Hits New 52-Week High at $68.18 - Markets Mojo
Understanding Monopar Therapeutics Inc.’s price movementSell Signal & Weekly Return Optimization Plans - newser.com
Stop Loss: Will Monopar Therapeutics Inc benefit from sector rotationFed Meeting & Reliable Volume Spike Alerts - خودرو بانک
Quarterly Recap: What is Pearson plc Depositary Receipts 5 year growth outlookEarnings Miss & Low Risk Growth Stock Ideas - خودرو بانک
H.C. Wainwright Maintains Monopar Therapeutics(MNPR.US) With Buy Rating, Maintains Target Price $70 - 富途牛牛
Is Monopar Therapeutics Inc. stock ready for a breakoutGDP Growth & Safe Entry Trade Reports - newser.com
Monopar Therapeutics (NASDAQ:MNPR) Receives “Buy” Rating from BTIG Research - Defense World
Monopar Therapeutics Inc Stock (MNPR) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):